Evaxion Biotech A/S (EVAX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVAX Stock Price Chart Interactive Chart >
EVAX Price/Volume Stats
| Current price | $1.61 | 52-week high | $3.52 |
| Prev. close | $1.60 | 52-week low | $1.41 |
| Day low | $1.57 | Volume | 175,426 |
| Day high | $1.65 | Avg. volume | 779,120 |
| 50-day MA | $1.85 | Dividend yield | N/A |
| 200-day MA | $2.28 | Market Cap | 38.37M |
Evaxion Biotech A/S (EVAX) Company Bio
Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.
Latest EVAX News From Around the Web
Below are the latest news stories about EVAXION BIOTECH A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.
Evaxion receives FDA fast-track designation for personalized cancer immunotherapyCOPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA®.In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial, |
Evaxion Biotech Gets FDA Approval To Proceed With Clinical Phase 2b Study For EVX-01Biotech company Evaxion Biotech A/S (EVAX) announced Tuesday that the U.S. Food and Drug Administration or FDA, determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. |
Evaxion''s stock soars after getting FDA approval for mid-stage cancer trialU.S.-listed shares of Evaxion Biotech A/S undefined jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration… |
XPEV, LI and BILI are among pre market gainersGorilla Technology Group (GRRR) +42%. Chemomab Therapeutics (CMMB) +38% as NASH candidate meets main goal in Phase 2 trial.Evaxion Biotech (EVAX) +21% receives approval from FDA… |
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. In November |
EVAX Price Returns
| 1-mo | -9.30% |
| 3-mo | -36.61% |
| 6-mo | -45.79% |
| 1-year | -48.73% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -9.30% |
| 2022 | -59.84% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...